Table 3 Correlation between Bmi-1 expression and the clinicopathologic features of breast cancer
|  | Bmi-1 Expression | Total | χ 2 | P-value | |
|---|---|---|---|---|---|
| Â | Low | High | Â | Â | Â |
| Â | N (%) | N (%) | N (%) | Â | Â |
Age | Â | Â | Â | 0.36 | 0.551 |
   ≤45 year | 26 (26.3) | 73 (73.7) | 99 (41.2) |  |  |
   >45 year | 42 (29.8) | 99 (70.2) | 141 (58.8) |  |  |
T Classification | Â | Â | Â | 30.92 | <0.001 |
   T1 | 26 (57.8) | 19 (42.2) | 45 (17.9) |  |  |
   T2 | 35 (25.9) | 100 (74.1) | 135 (53.6) |  |  |
   T3 | 9 (17.3) | 43 (82.7) | 52 (20.6) |  |  |
   T4 | 0 (0.0) | 20 (100.0) | 20 (7.9) |  |  |
N Classification | Â | Â | Â | 46.45 | <0.001 |
   N0 | 48 (53.3) | 42 (46.7) | 90 (35.7) |  |  |
   N1 | 20 (15.2) | 112 (84.8) | 132 (52.4) |  |  |
   N2 | 0 (0.0) | 22 (100.0) | 22 (8.7) |  |  |
   N3 | 2 (25.0) | 6 (75.0) | 8 (3.2) |  |  |
M Classification | Â | Â | Â | 14.87 | <0.001 |
   M0 | 68 (32.9) | 139 (67.1) | 207 (82.7) |  |  |
   M1 | 2 (4.4) | 43 (95.6) | 45 (17.9) |  |  |
Clinical Stage | Â | Â | Â | 82.06 | <0.001 |
   I | 16 (69.6) | 7 (30.4) | 23 (9.1) |  |  |
   II | 48 (51.1) | 46 (48.9) | 94 (37.3) |  |  |
   III | 4 (4.4) | 86 (95.6) | 90 (35.7) |  |  |
   IV | 2 (4.4) | 43 (95.6) | 45 (17.9) |  |  |
ER Presence | Â | Â | Â | 1.53 | 0.217 |
   Negative | 38 (31.4) | 83 (68.6) | 121 (48.0) |  |  |
   Positive | 32 (24.4) | 99 (75.6) | 131 (52.0) |  |  |
PR Presence | Â | Â | Â | 0.04 | 0.837 |
   Negative | 29 (27.1) | 78 (72.9) | 107 (42.5) |  |  |
   Positive | 41 (28.3) | 104 (71.7) | 145 (57.5) |  |  |
HER-2 Presence | Â | Â | Â | 0.71 | 0.400 |
   Negative | 17 (33.3) | 34 (66.7) | 51 (32.1) |  |  |
   Positive | 29 (26.9) | 79 (73.1) | 108 (67.9) |  |  |